Редактирование: ARMS2

Age-related maculopathy susceptibility protein 2

==Publications==

{{medline-entry
|title=Benefits, Potential Harms, and Optimal Use of Nutritional Supplementation for Preventing Progression of Age-Related Macular Degeneration.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/27866147
|abstract=To briefly review age-related macular degeneration (AMD), the main findings from the Age Related Eye Disease Study (AREDS) report number 8 on the use of nutritional supplements for AMD, and to focus on data suggesting that supplement use should be guided using genetic testing of AMD risk genes. A literature search (January 2001 through October 26, 2016) was conducted using MEDLINE and the following MeSH terms: Antioxidants/therapeutic use, Genotype, Macular Degeneration/drug therapy, Macular degeneration/genetics, Dietary Supplements, Proteins/genetics, and Zinc Compounds/therapeutic use. Bibliographies of publications identified were also reviewed. English-language studies assessing AREDS supplement response in patients with AMD in relation to complement factor H gene ( [[CFH]]) and age-related maculopathy susceptibility 2 gene ( [[ARMS2]]) risk alleles were evaluated. Three of the 4 studies demonstrated a treatment interaction between [[ARMS2]] and [[CFH]] genotypes and a differential response to supplements. The fourth study documented an interaction for the [[CFH]] genotype only. Reported response interactions included attenuated response, no response, and good response, whereas a subset showed increased progression of AMD. Conversely, one study reported no interactions between [[CFH]] and [[ARMS2]] risk alleles and response to supplements. The weight of the evidence supports using genetic testing to guide selection of ocular vitamin use. This approach will avoid using supplements that could speed the progression of AMD in vulnerable patients, avoid using supplements that will have little to no effect in others, and result in appropriately using supplements in those that are likely to derive meaningful benefits.
|mesh-terms=* Alleles
* Antioxidants
* Complement Factor H
* Dietary Supplements
* Disease Progression
* Dose-Response Relationship, Drug
* Female
* Genotype
* Humans
* Macular Degeneration
* Male
* Middle Aged
* Polymorphism, Single Nucleotide
* Proteins
* Risk Factors
* Treatment Outcome
* Vitamins
|keywords=* Aging
* Drug Safety
* Nutrition
* Opthalmology
* Pharmacogenetics and Pharmacogenomics
|full-text-url=https://sci-hub.do/10.1177/1060028016680643
}}
{{medline-entry
|title=A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/27500671
|abstract=Age-related diseases are becoming increasingly prevalent and the burden continues to grow as our population ages. Effective treatments are necessary to lessen the impact of debilitating conditions but remain elusive in many cases. Only by understanding the causes and pathology of diseases associated with aging, can scientists begin to identify potential therapeutic targets and develop strategies for intervention. The most common age-related conditions are neurodegenerative disorders such as Parkinson's disease and blindness. Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly. Genome wide association studies have previously identified loci that are associated with increased susceptibility to this disease and identified two regions of interest: complement factor H ([[CFH]]) and the 10q26 locus, where the age-related maculopathy susceptibility 2 ([[ARMS2]]) and high-temperature requirement factor A1 (HtrA1) genes are located. [[CFH]] acts as a negative regulator of the alternative pathway (AP) of the complement system while HtrA1 is an extracellular serine protease. [[ARMS2]] is located upstream of HtrA1 in the primate genome, although the gene is absent in mice. To study the effects of these genes, humanized knock-in mouse lines of Cfh and [[ARMS2]], knockouts of Cfh, HtrA1, HtrA2, HtrA3 and HtrA4 as well as a conditional neural deletion of HtrA2 were generated. Of all the genetically engineered mice produced only mice lacking HtrA2, either systemically or in neural tissues, displayed clear phenotypes. In order to examine these mice thoroughly and systematically, an initial phenotyping schedule was established, consisting of a series of tests related to two main diseases of interest: AMD and Parkinson's. Genetically modified mice can be subjected to appropriate experiments to identify phenotypes that may be related to the associated diseases in humans. A phenotyping regimen with a mitochondrial focus is presented here alongside representative results from the tests of interest.
|mesh-terms=* Aging
* Animals
* Complement Factor H
* Disease Models, Animal
* Gene Knock-In Techniques
* Genotype
* High-Temperature Requirement A Serine Peptidase 1
* Humans
* Mice
* Mice, Knockout
* Mice, Transgenic
* Phenotype
* Polymorphism, Single Nucleotide
* Proteins
* Serine Endopeptidases

|full-text-url=https://sci-hub.do/10.3791/54136
}}
{{medline-entry
|title=Mesopic Pelli-Robson contrast sensitivity and MP-1 microperimetry in healthy ageing and age-related macular degeneration.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/27225020
|abstract=To determine whether decreasing illumination of the Pelli-Robson contrast sensitivity ([[CS]]) chart and MP-1 microperimeter to low mesopic conditions is more sensitive to vision changes occurring with healthy ageing and in early and intermediate age-related macular degeneration (AMD) and whether these mesopic tests can differentiate visual function between healthy older participants with and without AMD risk genotypes. Retinal sensitivity was measured in 98 healthy participants (19-85 years) and 21 AMD (AREDS Grade 2/3) patients (73.9 ± 6.5 years) using the Pelli-Robson [[CS]] chart and MP-1 microperimeter under low mesopic and standard illumination. The effect of ageing and AMD on retinal sensitivity was estimated using regression analysis. Healthy older participants (>50 years; n = 24) were genotyped for AMD risk genes [[CFH]] and/or [[ARMS2]] and retinal sensitivity was compared between genotypes. With healthy ageing, photopic and mesopic Pelli-Robson [[CS]] showed a similar decline (-0.004 log [[CS]]/year). In AMD, photopic [[CS]] showed a similar decline to healthy ageing (-0.004 log [[CS]]/year) while mesopic [[CS]] was significantly reduced (-0.007 log [[CS]]/year). Both standard and low mesopic microperimetry showed a significant decline (-0.51 and -0.73% contrast/year) with healthy ageing and greater decline (-0.73 and -0.99% contrast/year) with AMD onset. Pelli-Robson [[CS]] and microperimetry sensitivity did not differ between AMD risk genotypes in healthy participants. Mesopic Pelli-Robson [[CS]] detects functional deficits before photopic [[CS]] in early and intermediate AMD that can be differentiated from ageing. This test can be easily administered in clinical practice and may provide a means for early detection of retinal dysfunction.
|mesh-terms=* Adult
* Aged
* Aged, 80 and over
* Aging
* Complement Factor H
* Contrast Sensitivity
* Female
* Genotype
* Healthy Volunteers
* Humans
* Macular Degeneration
* Male
* Mesopic Vision
* Middle Aged
* Proteins
* Retina
* Vision Tests
* Visual Field Tests
* Visual Fields
* Young Adult
|keywords=* contrast sensitivity
* macular degeneration
* mesopic
* microperimetry
|full-text-url=https://sci-hub.do/10.1111/aos.13112
}}
{{medline-entry
|title=[Age-related Macular Degeneration in the Japanese].
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/27164756
|abstract=Age-related macular degeneration (AMD) in the Japanese often shows different clinical features from those described in Caucasians. For example, we often observe choroidal neovascularization (CNV) in elderly patients without drusen in the fundus. The high incidence of polypoidal choroidal vasculopathy (PCV) in AMD among Japanese is well-known. The reason why such differences occur in clinical manifestations of AMD has been one of my main interests. In this review article, I will discuss the characteristics of AMD in the Japanese population, as found in our recent study. I. Prevalence and clinical characteristics of AMD in the Japanese population. Cohort studies are important to determine the prevalence and incidence of diseases. In Japan, cohort studies began to be carried out rather late compared with Western countries. Although good cohort studies from Japan are reported in the literature, the size of the cohorts was not sufficiently large to determine the prevalence of AMD. However, a recent meta-analysis of Asian cohorts has shown that the prevalence of late AMD in Asians is not different from that reported in Caucasians. On the other hand, the prevalence of early AMD appears lower in the Japanese than in Caucasians. Recently, we have published the results of the Nagahama Cohort study. In this cohort study, we found a high prevalence of drusen. It seems that the incidence of dry AMD is likely to increase among Japanese. In Japan, most retina specialists classify AMD into three categories : typical AMD, PCV, and retinal angiomatous proliferation (RAP). However, there are no definite diagnostic criteria to distinguish between the three conditions. To compare the clinical features of Japanese and Western cases of AMD, and to determine the incidence of the three types of AMD, we exchanged data about 100 consecutive cases between Kyoto University and Centre d'Ophtalmologie de Paris, France. Interestingly, the diagnoses made by the two institutes were not always in agreement. We also found more cases of PCV among the Japanese than among the French. II. PCV. About 50% of exudative AMD cases in the Japanese population are PCV. Because of its peculiar angiographic findings, PCV has long been considered to be a distinct clinical entity different from the usual exudative AMD. Also, there have been serious discussions on the nature of PCV. In our analyses, about 20% of PCV cases show rather large lesion sizes that exceed the vascular arcade. Scar formation in the macula and compromised vision are frequent findings in such cases. The occurrence of PCV in the inferior staphyloma or in angioid streaks shows heterogeneity in PCV. These findings suggest that PCV may be a finding on indocyanine green angiography rather than a distinct clinical entity. Spectral domain OCT examination shows that the branching vascular network of PCV is located between the retinal pigment epithelium and Bruch's membrane. In cases with retinal pigment epithelial detachment, CNV from the branching vascular network was found to extend along the roof of the detached retinal pigment epithelium. Such findings show that the branching vascular network of PCV is type 1 CNV. Complement factor H ([[CFH]]) and age-related maculopathy 2 ([[ARMS2]])/High temperature requirement 1 (HTRA1) located on chromosome 10 (10q26) are well-established disease susceptible genes of AMD. In the Japanese, the prevalence of [[CFH]] Y402H gene polymorphism is low and [[ARMS2]]/HITRA1 plays a more important role in the development of AMD. In [[ARMS2]] A69S polymorphism, a large deletion/insertion (443de1/54ins) that is reported in Caucasians was also found in Japanese. Thus, the genetic background of Caucasian and Japanese AMD is quite similar, as is also the case with exudative AMD and PCV. Our findings show that PCV is not a distinct clinical entity but is a subtype of exudative AMD. III. Exudative AMD with choroidal vascular hyperpermeability. Choroidal vascular hyperpermeability observed in central serous chorioretinopathy can be found in about 20% to 30% of exudative AMD cases in Japanese. Such cases often show a thick choroid, lack of drusen, and rather good visual prognosis with slow progression of the disease. Recently, "pachychoroid neovasculopathy" has been described by a group from New York. Such cases of AMD with choroidal vascular hyperpermeability, a thick choroid, and lack of drusen appears to belong to pachychoroid neovasculopathy. We studied the risk allele frequencies of [[CFH]] I62V and [[ARMS2]] A69S gene polymorphisms in three groups : usual exudative AMD, pachychoroid neovasculopathy, and normal controls. Interestingly, cases of pachychoroid neovasculopathy show different gene polymorphisms of [[CFH]] I62V and [[ARMS2]] A69S from the usual cases of exudative AMD and a more similar pattern to normal controls. Therefore, the possible mechanisms of the CNV development in such cases may differ from the classic well-documented drusen-dependent pathways. IV. Atrophic AMD in Japanese. Data from the Nagahama Cohort study show an increasing prevalence of drusen in Japanese. Recently, more extensive information on drusen has become available and the redefinition of drusen is currently in progress. In particular, the importance of reticular pseudodrusen (RPD) is more widely appreciated. This type of drusen is often found in Japanese AMD. Although the nature and location of RPD are still debatable, many investigators believe that this type of drusen is located under the sensory retina rather than under Bruch's membrane. In our analyses, RPD was found in 18.4% of late AMD cases in Japanese. It was more common in eyes with RAP or atrophic AMD and was seldom found in PCV. [[ARMS2]] A69S gene polymorphism was found more frequently in cases of exudative AMD with RPD, than in cases of exudative AMD without RPD. Eyes with RPD show a thin choroid and diminished vascular densities of choroidal vessels.
|mesh-terms=* Aging
* Eye Diseases
* Humans
* Japan
* Macular Degeneration
* Neovascularization, Pathologic


}}
{{medline-entry
|title=Prevalence and Genetic Characteristics of Geographic Atrophy among Elderly Japanese with Age-Related Macular Degeneration.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/26918864
|abstract=To investigate the prevalence and genetic characteristics of geographic atrophy (GA) among elderly Japanese with advanced age-related macular degeneration (AMD) in a clinic-based study. Two-hundred and ninety consecutive patients with advanced AMD were classified into typical neovascular AMD, polypoidal choroidal vasculopathy (PCV), retinal angiomatous proliferation (RAP) or geographic atrophy (GA). Genetic variants of [[ARMS2]] A69S (rs10490924) and [[CFH]] I62V (rs800292) were genotyped using TaqMan Genotyping Assays. The clinical and genetic characteristics were compared between patients with and without GA. The number of patients diagnosed as having typical neovascular AMD, PCV, RAP and GA were 98 (33.8%), 151 (52.1%), 22 (7.5%) and 19 (6.6%), respectively. Of 19 patients with GA, 13 patients (68.4%) had unilateral GA with exudative AMD in the contralateral eye. Patients with GA were significantly older, with a higher prevalence of reticular pseudodrusen, bilateral involvement of advanced AMD and T-allele frequency of [[ARMS2]] A69S compared with those with typical AMD and PCV; although there were no differences in the genetic and clinical characteristics among patients with GA and RAP. The prevalence of GA was 6.6% among elderly Japanese with AMD. Patients with GA and RAP exhibited genetic and clinical similarities.
|mesh-terms=* Aged
* Aged, 80 and over
* Aging
* Asian Continental Ancestry Group
* Blindness
* Choroid
* Choroidal Neovascularization
* Complement Factor I
* Female
* Gene Frequency
* Geographic Atrophy
* Humans
* Japan
* Male
* Prevalence
* Proteins
* Retrospective Studies

|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769020
}}
{{medline-entry
|title=Assessing susceptibility to age-related macular degeneration with proteomic and genomic biomarkers.
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/19202148
|abstract=Age-related macular degeneration (AMD) is a progressive disease and major cause of severe visual loss. Toward the discovery of tools for early identification of AMD susceptibility, we evaluated the combined predictive capability of proteomic and genomic AMD biomarkers. We quantified plasma carboxyethylpyrrole (CEP) oxidative protein modifications and CEP autoantibodies by ELISA in 916 AMD and 488 control donors. CEP adducts are uniquely generated from oxidation of docosahexaenoate-containing lipids that are abundant in the retina. Mean CEP adduct and autoantibody levels were found to be elevated in AMD plasma by approximately 60 and approximately 30%, respectively. The odds ratio for both CEP markers elevated was 3-fold greater or more in AMD than in control patients. Genotyping was performed for AMD risk polymorphisms associated with age-related maculopathy susceptibility 2 ([[ARMS2]]), high temperature requirement factor A1 ([[HTRA1]]), complement factor H, and complement [[C3]], and the risk of AMD was predicted based on genotype alone or in combination with the CEP markers. The AMD risk predicted for those exhibiting elevated CEP markers and risk genotypes was 2-3-fold greater than the risk based on genotype alone. AMD donors carrying the [[ARMS2]] and [[HTRA1]] risk alleles were the most likely to exhibit elevated CEP markers. The results compellingly demonstrate higher mean CEP marker levels in AMD plasma over a broad age range. Receiver operating characteristic curves suggest that CEP markers alone can discriminate between AMD and control plasma donors with approximately 76% accuracy and in combination with genomic markers provide up to approximately 80% discrimination accuracy. Plasma CEP marker levels were altered slightly by several demographic and health factors that warrant further study. We conclude that CEP plasma biomarkers, particularly in combination with genomic markers, offer a potential early warning system for assessing susceptibility to this blinding, multifactorial disease.
|mesh-terms=* Aging
* Autoantibodies
* Biomarkers
* Case-Control Studies
* Disease Susceptibility
* Enzyme-Linked Immunosorbent Assay
* Genome
* High-Temperature Requirement A Serine Peptidase 1
* Humans
* Macular Degeneration
* Polymorphism, Genetic
* Proteins
* Proteome
* Serine Endopeptidases

|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2690477
}}